Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Wilms Tumor × Isotretinoin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroblastoma 3 Leukemia 2 Kidney Neoplasms 2 Carcinoma, Renal Cell 2 Wilms Tumor 1 Thrombocytopenia 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Blast Crisis 1 Anemia, Refractory, with Excess of Blasts 1 Anemia, Refractory 1

Interventions

Temozolomide 3 Filgrastim 2 Drug Therapy 2 talazoparib 1 sargramostim 1 pembrolizumab 1 oblimersen 1 irinotecan sucrosofate 1 etoposide phosphate 1 entrectinib 1 X-Rays 1 Vincristine 1 Specimen Handling 1 Radiotherapy 1 Radiosurgery 1 Proteasome Inhibitors 1 Phantoms, Imaging 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 Monatide (IMS 3015) 1 Microarray Analysis 1 Lenalidomide 1 Isotretinoin 1 Irinotecan 1 Immunomodulating Agents 1 Immunohistochemistry 1 Ifosfamide 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Etoposide 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05384821 2026-03-18

MetroWilms

Centre Oscar Lambret

Phase 1/2 Recruiting

Kidney Neoplasms, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡